Quantum Biopharma (NASDAQ:QNTM) Posts Earnings Results, Misses Expectations By $2.57 EPS
by Doug Wharley · The Cerbat GemQuantum Biopharma (NASDAQ:QNTM – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($3.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($2.57), Zacks reports.
Quantum Biopharma Price Performance
Shares of Quantum Biopharma stock traded down $0.08 during midday trading on Wednesday, reaching $5.28. The company had a trading volume of 205,707 shares, compared to its average volume of 429,681. The stock has a fifty day moving average price of $3.65 and a 200 day moving average price of $6.41. Quantum Biopharma has a fifty-two week low of $2.07 and a fifty-two week high of $38.25.
Hedge Funds Weigh In On Quantum Biopharma
An institutional investor recently bought a new position in Quantum Biopharma stock. Jane Street Group LLC acquired a new position in Quantum Biopharma Ltd. (NASDAQ:QNTM – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 10,892 shares of the company’s stock, valued at approximately $80,000. Jane Street Group LLC owned 0.29% of Quantum Biopharma at the end of the most recent reporting period. 1.24% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of analysts have recently commented on the company. Wall Street Zen raised Quantum Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of Quantum Biopharma in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Quantum Biopharma currently has a consensus rating of “Sell”.
Check Out Our Latest Research Report on QNTM
Quantum Biopharma Company Profile
Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.